Other Routes of Protein and Peptide Delivery: Transdermal, Topical, Uterine, and Rectal - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 658

[46] Sarpotdar PP, Daniels CR. Use of polymeric buffers to facilitate iontophoretic transport
of drugs. Pharm Res 1990;7:(Suppl.)S185.
[47] Santi P, Colombo P, Bettini R, Catellani PL, Minutello A, Volpato NM. Drug reservoir
composition and transport of salmon calcitonin in transdermal iontophoresis. Pharm Res
1997;14:63-6.
[48] Coderch L, Oliva M, Pons L, Parra JL. Percutaneous penetration in vivo of amino acids.
Int J Pharm 1994;111:7-14.
[49] Wearley LL, Tojo K, Chien YW. A numerical approach to study the effect of binding on
the iontophoretic transport of a series of amino acids. J Pharm Sci 1990;79:992-8.
[50] Green PG, Hinz RS, Cullander C, Yamane G, Guy RH. Iontophoretic delivery of amino
acids and amino acid derivatives across the skin in vitro . Pharm Res 1991;8:1113-20.
[51] Burnette RR, Marrero D. Comparison between the iontophoretic and passive transport
of thyrotropin releasing hormone across excised nude mouse skin. J Pharm Sci 1986;75:
738-43.
[52] Magnusson BM, Runn P, Karlsson K, Koskinen LOD. Terpenes and ethanol enhance the
transdermal permeation of the tripeptide thyrotropin releasing hormone in human epider-
mis. Int J Pharm 1997;157:113-21.
[53] Green P, Shroot B, Bernerd F, Pilgrim WR, Guy RH. In vitro and in vivo iontophoresis of
a tripeptide across nude rat skin. J Control Release 1992;20:209-17.
[54] Gupta SK, Kumar S, Bolton S, Behl CR, Malick AW. Optimization of iontophoretic trans-
dermal delivery of a peptide and a non-peptide drug. J Control Release 1994;30:253-61.
[55] Ruland A, Rohr U, Kreuter J. Transdermal delivery of the tetrapeptide hisetal (melanotro-
pin (6-9) and amino acids: their contribution to the elucidation of the existence of an
“aqueous pore” pathway. Int J Pharm 1994;107:23-8.
[56] Heit MC, Monteiroriviere NA, Jayes FL, Riviere JE. Transdermal iontophoretic deliv-
ery of luteinizing hormone releasing hormone (LHRH): effect of repeated administration.
Pharm Res 1994;11:1000-3.
[57] Meyer BR, Kreis W, Eschbach J. Successful transdermal administration of thera-
peutic doses of a polypeptide to normal human volunteers. Clin Pharmacol Ther Ser
1988;44:607-12.
[58] Lelawongs P, Liu J, Chien YW. Transdermal iontophoretic delivery of arginine-vasopres-
sin (II): evaluation of electrical and operational factors. Int J Pharm 1990;61:179-88.
[59] Craane-van-hinsberg WHM, Bax L, Flinterman NHM, Verhoef J, Junginger HE, et al.
Iontophoresis of a model peptide across human skin in vitro : effects of iontophoresis pro-
tocol, pH, and ionic strength on peptide flux and skin impedance. Pharm Res 1994;11:
1296-300.
[60] Banga AK, Katakam M, Mitra R. Transdermal iontophoretic delivery and degradation of
vasopressin across human cadaver skin. Int J Pharm 1995;116:211-16.
[61] Lelawongs P, Liu J, Siddiqui O, Chien YW. Transdermal iontophoretic delivery of argi-
nine-vasopressin (I): physicochemical considerations. Int J Pharm 1989;56:13-22.
[62] Knoblauch P, Moll F. In vitro pulsatile and continuous transdermal delivery of buserelin
by iontophoresis. J Control Release 1993;26:203-12.
[63] Morimoto K, Iwakura Y, Nakatani E, Miyazaki M, Tojima H. Effects of proteolytic
enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of
calcitonin in rats. J Pharm Pharmacol 1992;44:216-18.
[64] Chang S, Hofmann GA, Zhang L, Deftos LJ, Banga AK. Transdermal iontophoretic
delivery of salmon calcitonin. Int J Pharm 2000;200:107-13.
[65] Thysman S, Hanchard C, Preat V. Human calcitonin delivery in rats by iontophoresis.
J Pharm Pharmacol 1994;46:725-30.